New trial
Phase II Study of Lenvatinib & Pembrolizumab (PD-1) in Unresectable Anaplastic Thyroid Cancer
- Trial ID
- NCT04171622 on ClinicalTrials.gov
- Cancer type
- Thyroid Carcinoma
- Published in
- New in Oncology - May 29, 2025
M.D. Anderson is evaluating the combination of lenvatinib, a multikinase inhibitor, with pembrolizumab, a PD-1 monoclonal antibody, in patients with stage IVB unresectable or stage IVC metastatic anaplastic thyroid cancer to determine if the dual approach improves outcomes compared to either agent alone.
More in thyroid cancer
-
Trial result · Oct 22, 2026 · NCT03899792
Selpercatinib (selective RET inhibitor) posts 53% ORR with 2-year durability in pediatric RET-altered tumors -
Trial result · Aug 13, 2026 · NCT04940052
Dabrafenib + trametinib (BRAF/MEK) cuts progression risk in BRAF V600E thyroid cancer -
Trial result · Aug 13, 2026 · NCT03181100
Atezolizumab (PD-L1) + MAPK-targeted therapy links ATC long survival to “inflamed + differentiated” tumors, not BRAF/RAS status -
Trial result · Jul 8, 2026 · NCT03037385
Pralsetinib (selective RET inhibitor) drives 92% ORR in pretreated RET fusion+ thyroid cancer; 68% ORR in RET-altered MTC -
Trial result · Jul 8, 2026 · NCT03669432
THYRO-RT Finds No Significant LRR Benefit From Adjuvant EBRT in High-Risk Thyroid Cancer